open access

Vol 75, No 2 (2007)
ORIGINAL PAPERS
Published online: 2007-06-03
Submitted: 2013-02-22
Get Citation

Menopausal status and severity of obstructive sleep apnoea (OSA) in females

Robert Pływaczewski, Michał Bednarek, Przemysław Bieleń, Luiza Jonczak, Dorota Górecka, Paweł Śliwiński
Pneumonol Alergol Pol 2007;75(2):129-133.

open access

Vol 75, No 2 (2007)
ORIGINAL PAPERS
Published online: 2007-06-03
Submitted: 2013-02-22

Abstract


Introduction: Prevalence of obstructive sleep apnoea (OSA) is higher in postmenopausal females. The aim of this study was to compare OSA severity in postmenopausal females (group E-) and females with preserved estrogen activity (premenopausal or on hormonal replacement therapy - group E+).
Material and methods: We studied 147 OSA females in mean age 58.1 ± 9.4 years. Subjects presented obesity (BMI = 34 ± ± 7.9 kg/m2) and moderate or severe disease (AHI = 35.9 ± 20.9), SaO2 mean - 89.4 ± 5.8%. Group (E-) consisted of 116 pts (75.5%) and group (E+) of 36 pts (24.5%).
Results: Group (E+) presented more severe OSA (AHI/RDI = 42 ± 26.6) and obesity (BMI = 37.6 ± 10.1 kg/m2) when compared to group E- (AHI/RDI = 33.9 ± 18.4; p = 0.04 and BMI - 32.8 ± 6.7 kg/m2; p = 0.001). In multiple linear regression analysis we found significant negative correlation between AHI and age (β = -0.29, p = 0.03). After adjustment for BMI and age (analysis of covariance) significant difference was still present between both groups (R = 0.24, p = 0.03).
Conclusions: Majority of OSA females qualified to CPAP therapy were postmenopausal (75.5%). Severity of OSA (AHI/RDI) after adjustment for age and BMI was higher in group (E+).

Abstract


Introduction: Prevalence of obstructive sleep apnoea (OSA) is higher in postmenopausal females. The aim of this study was to compare OSA severity in postmenopausal females (group E-) and females with preserved estrogen activity (premenopausal or on hormonal replacement therapy - group E+).
Material and methods: We studied 147 OSA females in mean age 58.1 ± 9.4 years. Subjects presented obesity (BMI = 34 ± ± 7.9 kg/m2) and moderate or severe disease (AHI = 35.9 ± 20.9), SaO2 mean - 89.4 ± 5.8%. Group (E-) consisted of 116 pts (75.5%) and group (E+) of 36 pts (24.5%).
Results: Group (E+) presented more severe OSA (AHI/RDI = 42 ± 26.6) and obesity (BMI = 37.6 ± 10.1 kg/m2) when compared to group E- (AHI/RDI = 33.9 ± 18.4; p = 0.04 and BMI - 32.8 ± 6.7 kg/m2; p = 0.001). In multiple linear regression analysis we found significant negative correlation between AHI and age (β = -0.29, p = 0.03). After adjustment for BMI and age (analysis of covariance) significant difference was still present between both groups (R = 0.24, p = 0.03).
Conclusions: Majority of OSA females qualified to CPAP therapy were postmenopausal (75.5%). Severity of OSA (AHI/RDI) after adjustment for age and BMI was higher in group (E+).
Get Citation

Keywords

obstructive sleep apnoea; females; postmenopausal; premenopausal; hormonal replacement therapy

About this article
Title

Menopausal status and severity of obstructive sleep apnoea (OSA) in females

Journal

Advances in Respiratory Medicine

Issue

Vol 75, No 2 (2007)

Pages

129-133

Published online

2007-06-03

Bibliographic record

Pneumonol Alergol Pol 2007;75(2):129-133.

Keywords

obstructive sleep apnoea
females
postmenopausal
premenopausal
hormonal replacement therapy

Authors

Robert Pływaczewski
Michał Bednarek
Przemysław Bieleń
Luiza Jonczak
Dorota Górecka
Paweł Śliwiński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl